Navigation Links
Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
Date:3/25/2009

RICHMOND, Va., March 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOB) and biopharmaceuticals, today announced that on Monday, March 23, 2009, NASDAQ issued a notice further extending the suspension of the rules requiring a minimum $1 closing bid price and those rules requiring a minimum market value of publicly held shares (MVPHS). The suspension will remain in effect through Friday, July 17, 2009, and the original rules will be reinstated on Monday, July 20, 2009. Based on NASDAQ's previous extension notice of the suspension of these rules on Friday, December 19, 2008, the original rules were due to be reinstated on Monday, April 20, 2009.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that closing conditions under our agreement with Merck & Co., Inc. may not be met, product candidates may fail in the clinic or may not be s
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
2. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
3. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
4. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
5. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
6. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
7. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
8. Insmed to Seek Shareholder Approval for Reverse Split
9. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
10. Insmed to Present at Biosimilars 2008 Conference
11. Insmed to Present at BioPharm Asia 2008 Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... to also Visit Detroit , ..., French Ambassador for International Investment, ...y, , , , ,What: Ambassador Appia is available to ...tiatives adopted by France to further develop the ...ation and development., , ,When: Available for Int...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--DowAgroSciencesCanada...adivisionofThompsonsLimitedofBlenheim,Ontario.Thea...es,currentseedsbusinessasthecompanyanticipatesthei...iencesHerbicideTolerantTraitTechnologyincornin2012..., "Thisacquisitionbringstogethertwostrongprogre...
(Date:11/24/2009)...re employment grew by 29,000 jobs in October, and... growth during the U.S. recession. However, clinic...ealth systems are coming closer to having to actua...trators. , (Vocus) Novemb...owing in October despite the shedding of jobs in m...
(Date:11/24/2009)...swire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),ab...rcializingnovelpainmanagementtherapies,announcedto...ficer,isscheduledtopresentatthe21stAnnualPiperJaff...TheNewYorkPalaceHotelinNewYork,NewYork. ,, Mr.D...llbeavailabletorespondtoquestionsduringthepresenta...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
....C., Feb. 25 Attagene Inc., a,biotechnology compa...duction analysis, announced today that one of the ...hip technology, the FACTORIAL(TM). In,advance onli...gei Romanov,with colleagues describes a novel and ...porting on the activity of a large panel of transc...
...b. 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA... Phase 3 clinical trial with AZ-004 (Staccato(R) l...e being developed for the treatment of,acute agita...order. Alexza,believes the novel, non-invasive nat...lting from inhaled loxapine administration via the...
...st to Assess Genetic Risk of Thrombosis Improves, ...with Batch Processing, SUNNYVALE, Calif., and LEX...epheid (Nasdaq: CPHD ) and Instrumentation Labora... today announced the release of the Xpert (TM),Hem...roduct under the,European Directive on In Vitro Di...
Other Biology Technology:Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 2Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 3Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 4Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 5
(Date:11/24/2009)...ion of a remarkable class of ring-shaped protein m...awrence Berkeley National Laboratory (Berkeley Lab... beamline at the Advanced Light Source (ALS). Thes...sion and replication, and are vital to the surviva...gents, such as the human papillomavirus, which has...
(Date:11/24/2009)...YORK (November 24, 2009) -- The Wildlife Conservat...ng that the last remaining population of Siberian ...e rising tide of poaching and habitat loss. , ...sian officials of what needs to be done to protect... , The report was released by the S...
(Date:11/24/2009)...sh food is a matter of debate. A high-profile stud...0 percent of their carbon from trees and leaves, e...ial and aquatic ecosystems. , But new research f... likely to be true. Algae provide a much richer di...esearch published this week in the Proceedings of...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 1European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 2Pioneer of Digital Place Based Media Joins World 26apos 3Bs Leading Blood Pressure and Health Kiosk Manufacturer 51199 1Pioneer of Digital Place Based Media Joins World 26apos 3Bs Leading Blood Pressure and Health Kiosk Manufacturer 51199 2Life Spine 28R 29 Announces FDA Clearance of FS3 28TM 29 Minimally Invasive Spinal System 51196 1
...l repairs or replicates its DNA, the resulting sin...mplex. In eukaryotes or organisms whose cells have...mplex called replication protein A (RPA). Research...ave now unearthed a novel RPA-like complex that sp...NA "tail" end of yeast chromosomes. , Their findin...
...he University of California, Santa Cruz, have dete...nzyme, or "ribozyme," that carries out a fundament...eir results provide insight into what may have bee...lions of years ago on the evolutionary path toward...wn today, the synthesis of DNA and RNA molecules i...
...ack baby" hysteria of the 1980s was greatly exagge...le but disabling cognitive impairments -- attentio...oblems. , A recent study by investigators at the ...velopment may help explain the long-term behaviora...al exposure to cocaine. In a recent issue of the J...
Other Biology News:DNA ends: Common tool, different job 2RNA enzyme structure offers a glimpse into the origins of life 2Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3
Rabbit Anti-SMURF 2 Polyclonal Antibody, Unconjugated from Abcam
... for spontaneous ligand immobilization can be coup...igen, or receptor to create an affinity matrix of ...e ligands via primary amines. Affi-Gel 10 gel coup...11; Affi-Gel 15 gel couples acidic proteins with p...
Anti-Monocarboxylate Transporter 2 (MCT2) Polyclonal Antibody, Unconjugated from CHEMICON
MagSi-S-SO3 2 from MagnaMedics Diagnostics B.V.
Biology Products: